Law Offices of Frank R. Cruz Encourages Baxter International, Inc. (BAX) Shareholders to Inquire About Securities Fraud Class Action

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased Baxter International, Inc. (“Baxter” or the “Company”) (NYSE: BAX) common stock between February 23, 2022 and July 30, 2025, inclusive (the “Class Period”). Baxter investors have until December 15, 2025 to file a lead plaintiff motion.

IF YOU SUFFERED A LOSS ON YOUR BAXTER INTERNATIONAL, INC. (BAX) INVESTMENTS, CLICK HERE TO SUBMIT A CLAIM TO POTENTIALLY RECOVER YOUR LOSSES IN THE ONGOING SECURITIES FRAUD LAWSUIT.

You can also contact the Law Offices of Frank R. Cruz to discuss your legal rights by email at [e-mail], by telephone at [phone], or visit our website at www.frankcruzlaw.com.

What Happened?

On April 7, 2025, a Missouri news outlet reported serious safety issues relating to inaccurate infusion rates with Baxter’s Novum IQ Large Volume Pump (“Novum LVP”), a device used for the controlled delivery of intravenous fluids, based on information from a whistleblower at a local hospital system. The whistleblower claimed that “patients should not be being treated with these pumps. These pumps are not safe.” The report led to the hospital system’s removal of all Novum LVPs.

Then, on April 24, 2025, Baxter sent warning letters to customers regarding a potential underinfusion risk associated with the Novum LVP, disclosing only one serious injury linked to this issue. On July 14, 2025, the Company issued a second warning letter repeating the underinfusion risk along with an additional overinfusion risk, revealing that it had received 79 reports of serious injury and two reports of patient deaths related to the Novum LVP. The FDA subsequently classified these issues as a Class I recall, its most serious designation, reflecting a risk of severe injury or death.

Then, on July 31, 2025, Baxter announced that it was “voluntarily and temporarily [pausing] shipments and planned installations of the Novum LVP” and that the Company was “unable to currently commit to an exact timing for resuming shipment and installation for Novum LVPs.”

On this news, Baxter’s stock price fell $6.24, or 22.4%, to close at $21.61 per share on July 31, 2025, thereby injuring investors.

What Is The Lawsuit About?

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the Novum LVP suffered systemic defects that caused widespread malfunctions, including underinfusion, overinfusion, and complete non-delivery of fluids, which exposed patients to risks of serious injury or death; (2) Baxter was notified of multiple device malfunctions, injuries, and deaths from these defects; (3) Baxter’s attempts to address these defects through customer alerts were inadequate remedial measures, when design flaws persisted and continued to cause serious harm to patients; (4) as a result, there was a heightened risk that customers would be instructed to take existing Novum LVPs out of service and that Baxter would completely pause all new sales of these pumps; and (5) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More:

If you purchased Baxter common stock, wish to learn more about this action, or have any questions concerning this announcement or your rights or interests with respect to these matters, please click HERE or contact us at:

Law Offices of Frank R. Cruz
2121 Avenue of the Stars, Suite 800
Telephone: [phone]
Email: [e-mail]
Visit our website at: www.frankcruzlaw.com

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.